latest news releases from the newsroom
Acura Pharmaceuticals, Inc.
Acura Pharmaceuticals, Inc. Names Garth Boehm, Ph.D. VP of Modified Release Dosage Form Development
PALATINE, Ill., March 26, 2009 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (Nasdaq:ACUR) is pleased to announce that Garth Boehm, Ph.D. has been named Vice President, Modified Release Dosage Form Development. Dr. Boehm, is currently employed as Vice President of Product Development at Actavis Pharmaceuticals and is expected to commence employment with Acura in May 2009.
Discovery Laboratories, Inc.
Discovery Labs Advances KL4 Surfactant Technology Platform With Lyophilized Formulation
WARRINGTON, Pa., March 26, 2009 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO) today announces that it has created a lyophilized formulation of its synthetic, peptide-containing KL4 surfactant technology. Lyophilized KL4 surfactant is being developed to support Discovery Labs' pipeline of surfactant product candidates including Surfaxin(r) (lucinactant as a liquid formulation) and Aerosurf(r) (lucinactant as an aerosolized formulation). Discovery Labs is developing a pipeline of surfactant-based therapies targeted to address several respiratory disorders associated with surfactant deficiency or dysfunction. Lyophilized KL4 surfactant is manufactured as a dry powder formulation that is reconstituted prior to use. Key next steps include planned discussions with global regulatory agencies intended to determine the development pathway leading to the initiation of a late-stage neonatal clinical trial program.